Trihexyphenidyl for dystonia in cerebral palsy

  1. To evaluate the effects of trihexyphenidyl on the World Health Organisation's (WHO) International Classification of Functioning, Disability and Health (ICF) domains of impairment, activity, and participation in individuals with dystonic cerebral palsy.
  2. To assess the type and incidence of adverse effects from the use of trihexyphenidyl in individuals with dystonic cerebral palsy.

This is a protocol.

Share/Save